Cempra, Inc. (NASDAQ:CEMP)‘s stock had its “hold” rating reissued by investment analysts at Jefferies Group LLC in a report issued on Thursday. They currently have a $3.00 price objective on the biotechnology company’s stock. Jefferies Group LLC’s price objective indicates a potential downside of 3.23% from the company’s current price.
Several other research firms also recently weighed in on CEMP. Roth Capital downgraded shares of Cempra from a “buy” rating to a “neutral” rating and reduced their price objective for the stock from $8.00 to $4.00 in a report on Thursday, August 10th. ValuEngine downgraded shares of Cempra from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd. Stifel Nicolaus reaffirmed a “hold” rating and issued a $4.00 price objective on shares of Cempra in a report on Thursday, August 10th. Finally, Zacks Investment Research cut shares of Cempra from a “buy” rating to a “hold” rating in a research report on Monday, August 14th. Four investment analysts have rated the stock with a sell rating, twelve have issued a hold rating, two have given a buy rating and one has given a strong buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $10.00.
Cempra (CEMP) opened at 3.10 on Thursday. Cempra has a 12-month low of $2.55 and a 12-month high of $26.95. The firm’s 50-day moving average is $3.23 and its 200 day moving average is $3.80. The stock’s market capitalization is $162.77 million.
Cempra (NASDAQ:CEMP) last posted its quarterly earnings data on Wednesday, August 9th. The biotechnology company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($0.32) by $0.09. The business had revenue of $0.86 million during the quarter, compared to the consensus estimate of $3.58 million. Cempra had a negative net margin of 560.40% and a negative return on equity of 53.99%. The company’s quarterly revenue was down 74.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.51) earnings per share. Equities research analysts anticipate that Cempra will post ($1.01) earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: “Cempra, Inc. (CEMP) Stock Rating Reaffirmed by Jefferies Group LLC” was published by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this report on another domain, it was copied illegally and republished in violation of U.S. & international trademark & copyright laws. The correct version of this report can be read at https://sportsperspectives.com/2017/09/16/cempra-inc-cemp-stock-rating-reaffirmed-by-jefferies-group-llc.html.
Hedge funds and other institutional investors have recently bought and sold shares of the business. Voya Investment Management LLC raised its holdings in Cempra by 34.1% during the 2nd quarter. Voya Investment Management LLC now owns 23,006 shares of the biotechnology company’s stock worth $106,000 after buying an additional 5,848 shares during the period. Janney Montgomery Scott LLC raised its holdings in Cempra by 35.6% during the 2nd quarter. Janney Montgomery Scott LLC now owns 25,900 shares of the biotechnology company’s stock worth $119,000 after buying an additional 6,800 shares during the period. Asset Management One Co. Ltd. acquired a new stake in Cempra during the 1st quarter worth about $106,000. LMR Partners LLP acquired a new stake in Cempra during the 2nd quarter worth about $149,000. Finally, Ameriprise Financial Inc. acquired a new stake in Cempra during the 2nd quarter worth about $164,000. Hedge funds and other institutional investors own 49.76% of the company’s stock.
Cempra Company Profile
Cempra, Inc is a clinical-stage pharmaceutical company. The Company focuses on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases. Its product, solithromycin (CEM-101), which is a macrolide and fluoroketolide, is being developed in oral capsules, intravenous (IV) and suspension formulations for the treatment of community-acquired bacterial pneumonia (CABP).
Receive News & Ratings for Cempra Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cempra Inc. and related companies with MarketBeat.com's FREE daily email newsletter.